Evaxion Biotech A/S宣布，与Evx-05相关的各项成本均已纳入公司现有预算框架之内，并未对现金储备产生额外冲击。这家生物技术企业的资金续航能力依然稳固，可持续延伸至2027年下半年。
公司将Evx-05项目的支出妥善安排于既定财务规划中，这一举措确保了研发推进的同时，不会侵蚀既有的现金流基础。市场关注的核心指标——现金跑道——依旧保持其预期的延展性，为公司后续的战略布局提供了充足的财务缓冲。
在当前生物科技行业普遍面临融资压力的背景下，Evaxion的这一财务安排展现出审慎的资源管理能力。通过将新增项目成本内化于既有预算结构，公司有效规避了因额外开支而可能引发的资金链紧张风险，为其在研管线的持续推动奠定了坚实的财务基石。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.